CHS on Facebook, Twitter and YouTube
Good news! Manulife to underwrite eligible Canadians who test HIV-positive
Click here to read Manulife’s press release.
Factor VIII and IX: CBS tender results announced
Canadian Blood Services Recombinant Factor VIII and Recombinant Factor IX Contracts and Contract Awards.
It is important to note that the decision surrounding these contracts was a unanimous one by the selection committee, involving experts from CBS, the Association of Hemophilia Clinic Directors of Canada, the Canadian Association of Nurses in Hemophilia Care and the Canadian Hemophilia Society. The evaluation was based on safety, efficacy, quality and cost.
These contracts will result in a large number of patients with hemophilia A switching products. Following similar tender processes in recent years in countries such as Ireland, the United Kingdom and Australia, resulting in massive product switching, no negative outcomes were observed. The province of Quebec went through a similar mass switch in rFVIII products (Helixate FS to Xyntha) one year ago, and the process went very smoothly.
See the Canadian Blood Services Question & Answer document entitled rFVIII and rFIX Request for Proposal: Product Supply and Transitioning for details on product switching.
The Q&A refers to “significant savings.” These are in the tens of millions of dollars annually.
While there are clear suggestions that patients using Kogenate FS switch to Bayer’s new product Kovaltry, an identical molecule, later this spring or summer, and that users of Advate, which will be phased out over the next several months, switch to Pfizer’s Xyntha, this document states that such decisions are made jointly by the physician and patient.
Octapharma’s Nuwiq is also being introduced into Canada. Biogen’s extended half-life Eloctate has been available since February.
With regard to factor IX, Pfizer’s Benefix remains the predominant product. Biogen’s extended half-life Alprolix is now available. The plasma-derived FIX product Immunine, while not part of the tender process, remains available.
2016 World Hemophilia Day
In Nova Scotia...
Surplus in the Trust Fund for the 1986-1990 Hepatitis C Settlement Agreement
The CHS, along with several other organizations, objects to the surplus being paid out to the federal government and strongly supports a Notice of Motion, which will be presented to the courts at a Joint Hearing in June, to enhance the benefits to claimants.
On March 17, the CHS put out a call for action asking community-based groups to endorse a statement objecting to the 86‐90 Trust Fund surplus being paid out to the federal government. Click here to read the statement.
To learn more, click here for a comprehensive Q&A document on the overall issue.
PRESS RELEASE - March 30, 2016
For more details.
MyCBDR app now available!
If you have not registered for MyCBDR yet, you can submit your request at www.mycbdr.ca/MyCBDR/Account/Register. Remember to select your HTC from the drop-down menu available at registration. The AHCDC and McMaster University are working continually to enrol more HTCs into the CBDR network. In case you belong to an HTC that is not yet using CBDR, you can still request a MyCBDR account by selecting “Holding Center for MyCBDR” as your HTC.
Please feel free to send in your questions, comments and feedback to email@example.com.
N.B. The French-language version of the app should soon be available.
National Family Inhibitor Workshop - May 13-15, 2016
The workshop provides an opportunity for parents to gain new knowledge from medical experts about treatment options and the management of inhibitors and to share their experiences in coping as families. And, for the children and adolescents, it will be a chance to meet other kids with inhibitors, learn about hemophilia and have fun.
If you are interested in attending, please contact your clinic nurse or the CHS national office (1-800-668-2686) for more information.
Me, the app that could end years of suffering for thousands of women
Click here to read the press release sent out on International Women's Day about this important new tool
CHS support to research and market studies
These studies, however, need our community to gather sufficient data to be relevant.
Please take the time to see what is presently happening with regards to research and market studies and to see if you could take an active part in them.
Click here for more details on the RESEARCH studies currently recruiting participants.
Click here for more details on the MARKET studies currently recruiting participants.
Products in the pipeline - NEW UPDATE (February 29, 2016)
Click here for more details.
Hemophilia Today - March 2016
2016-2020 CHS Strategic Plan
Menstrual Assessment Chart (PBAC)
E-novella spreading the word on bleeding disorders on Wattpad
Playing off the popular Harlequin romance genre, ‘A Negative’ tells the story of a young woman unknowingly living with von Willebrand disease. We’ve published the e-novella on Wattpad – the world’s largest online community of writers and readers – in order to connect with young women across Canada. This unique approach introduces the issue into a different medium, enabling us to speak to and educate an engaged but unsuspecting audience.
CLICK HERE for the press release.
CLICK HERE to read 'A Negative'.
A bandage is not enough.
HELP SPREAD THE WORD ABOUT INHERITED BLEEDING DISORDERS.
Click here for more information about this important public awareness and outreach campaign or to download promotional material.
You and your family depend on research...
Make a difference - Help save lives
We can stop the suffering of those living with hemophilia and other bleeding disorders. But we can't do it alone. Only with the generous financial support of caring Canadians can we make our dream come true.
To support us